At its meeting on 16 August 2022 the Transparency Council adopted Position No. 76/2022 on the evaluation of the drug Empliciti (elotuzumab) under the drug programme: ,,Treatment of Patients with Multiple Myeloma (ICD-10: C90.0)”.
At its meeting on 16 August 2022 the Transparency Council adopted Position No. 76/2022 on the evaluation of the drug Empliciti (elotuzumab) under the drug programme: ,,Treatment of Patients with Multiple Myeloma (ICD-10: C90.0)”.